Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1, RANDOMIZED, OPEN-LABEL, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE EFFECT OF PF-06865571 ON THE PHARMACOKINETICS OF METFORMIN IN HEALTHY ADULT SUBJECTS

Trial Profile

A PHASE 1, RANDOMIZED, OPEN-LABEL, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE EFFECT OF PF-06865571 ON THE PHARMACOKINETICS OF METFORMIN IN HEALTHY ADULT SUBJECTS

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2019

At a glance

  • Drugs PF 06865571 (Primary) ; Metformin
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Jan 2019 Planned End Date changed from 12 Feb 2019 to 13 Feb 2019.
    • 14 Dec 2018 Status changed from suspended to recruiting.
    • 07 Dec 2018 Planned End Date changed from 12 Mar 2019 to 12 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top